Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTAWNKZ)

• DTT Name: Norepinephrine transporter (NET)
• Synonyms: Solute carrier family 6 member 2; Sodium-dependent noradrenaline transporter; SLC6A2; NET1; NET; NAT1
• Gene Name: SLC6A2
• DTT Type: Successful target; [1]
• Related Disease:
  Acute pain [ICD-11: MG31]
  Attention deficit hyperactivity disorder [ICD-11: 6A05]
  Chronic pain [ICD-11: MG30]
  Corneal disease [ICD-11: 9A76-9A78]
  Depression [ICD-11: 6A70-6A7Z]
  Glaucoma [ICD-11: 9C61]
  Migraine [ICD-11: 8A80]
  Nicotine use disorder [ICD-11: 6C4A]
  Obesity [ICD-11: 5B80-5B81]
  Pain [ICD-11: MG30-MG3Z]
  Stomach cancer [ICD-11: 2B72]
• BioChemical Class: Neurotransmitter:sodium symporter
• UniProt ID: SC6A2_HUMAN
• TTD ID: T21945
• Sequence:
  MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG
  KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN
  REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW
  NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC
  LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY
  RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA
  IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS
  MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS
  ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF
  KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL
  VAQRDIRQFQLQHWLAI
• Function: Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
• Reactome Pathway: Na+/Cl- dependent neurotransmitter transporters (R-HSA-442660)

Molecular Interaction Atlas (MIA) of This DTT

28 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[2]
Amfepramone	DM9YSNQ	Migraine	8A80	Approved	[3], [4]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[5], [6]
Amoxapine	DMKITQE	Major depressive disorder	6A70.3	Approved	[7]
Atomoxetine	DM5L6HI	Attention deficit hyperactivity disorder	6A05.Z	Approved	[8], [9]
Bupropion	DM5PCS7	Smoking dependence	6C4A.2	Approved	[1]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[10]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[11]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
Desvenalfaxine succinate	DMJE6KO	Fibromyalgia	MG30.01	Approved	[12]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[13], [14]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[15], [16]
Iobenguane I-123	DM80OEZ	Neuroendocrine cancer	2B72.1	Approved	[17]
Levomilnacipran	DMV26S8	Fibromyalgia	MG30.01	Approved	[18]
Maprotiline	DMPWB7T	Major depressive disorder	6A70.3	Approved	[19]
Mazindol	DMZ36RN	Obesity	5B81	Approved	[20], [21]
Milnacipran	DMBFE74	Depression	6A70-6A7Z	Approved	[22]
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[23]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[24]
Phentermine	DMG60XN	Obesity	5B81	Approved	[25]
Protriptyline	DMNHTZI	Depression	6A70-6A7Z	Approved	[26]
Reboxetine	DM26PRD	Depression	6A70-6A7Z	Approved	[27]
Sibutramine	DMFJTDI	Obesity	5B81	Approved	[21]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[28]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[29]
Venlafaxine	DMR6QH0	Depression	6A70-6A7Z	Approved	[1]
Hypericum	DM8NWFD	N. A.	N. A.	Phase 4	[30]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[31]

17 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[17]
Bicifadine	DM42GP9	Chronic low back pain	MG30.02	Phase 3	[32]
Bupropion+Naltrexone	DMAR9ND	Obesity	5B81	Phase 3	[33]
Roclatan	DMVQ5X1	Glaucoma/ocular hypertension	9C61	Phase 3	[34]
Suronacrine maleate	DMH2FN1	Cognitive impairment	6D71	Phase 3	[35]
18F-LMI-1195	DM8JVIB	Heart failure	BD10-BD13	Phase 2	[36]
BLI-1005	DMYK1DR	Major depressive disorder	6A70.3	Phase 2	[37]
MCT-125	DMDR2SZ	Fatigue	MG22	Phase 2	[17]
Metaiodobenzylguanidine I-131	DMNST69	Neuroblastoma	2D11.2	Phase 2	[38]
NS 2359	DMI5HFU	Cocaine addiction	6C45.2	Phase 2	[39], [40]
PDC-1421	DMGP9VN	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[41]
Spiroglumide	DM7NJWY	Stomach disease	DA43-DA4Y	Phase 2	[42]
SPN-812	DMZIC4Q	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[37]
TD-9855	DMQD5NA	Pain	MG30-MG3Z	Phase 2	[43]
XEN-2174	DM0NFMS	Cancer related pain	MG30	Phase 2	[44]
BL-1021	DMAYSFK	Pain	MG30-MG3Z	Phase 1	[45]
GSK-1360707	DMZC9XU	Major depressive disorder	6A70.3	Phase 1	[46]

10 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DOV-216303	DMTE14H	Mood disorder	6A60-6E23	Discontinued in Phase 2	[39]
Esreboxetine	DMTUHWM	Fibromyalgia	MG30.01	Discontinued in Phase 2	[47]
Manifaxine	DMRN7GC	Major depressive disorder	6A70.3	Discontinued in Phase 2	[48]
Napitane mesilate	DMF9Y57	Major depressive disorder	6A70.3	Discontinued in Phase 2	[49]
NS-2389	DMVRJ8D	Major depressive disorder	6A70.3	Discontinued in Phase 2	[50]
R-sibutramine metabolite	DMPAH74	Attention deficit hyperactivity disorder	6A05.Z	Discontinued in Phase 2	[51]
Radafaxine	DMARQE0	Major depressive disorder	6A70.3	Discontinued in Phase 2	[52], [53]
SPD-473	DMTJNRL	Mood disorder	6A60-6E23	Discontinued in Phase 2	[54]
NSD-644	DMNL9DS	Neurological disorder	6B60	Discontinued in Phase 1	[55]
RG-7166	DMKLPMW	Major depressive disorder	6A70.3	Discontinued in Phase 1	[56]

173 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine	DM2TIU3	Discovery agent	N.A.	Investigative	[57]
(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine	DML68KX	Discovery agent	N.A.	Investigative	[58]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[59]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[59]
(R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol	DMBXRKS	Discovery agent	N.A.	Investigative	[60]
(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	DM74IWX	Discovery agent	N.A.	Investigative	[61]
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine	DM94B12	Discovery agent	N.A.	Investigative	[58]
(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile	DM134UV	Discovery agent	N.A.	Investigative	[58]
(R)-DULOXETINE	DMECK7H	Discovery agent	N.A.	Investigative	[62]
(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	DMJFH97	Discovery agent	N.A.	Investigative	[63]
(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide	DMQIUOB	Discovery agent	N.A.	Investigative	[63]
(R)-Norfluoxetine	DMS30KU	Discovery agent	N.A.	Investigative	[64]
(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine	DM5ILK1	Discovery agent	N.A.	Investigative	[58]
(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile	DM32PJ5	Discovery agent	N.A.	Investigative	[58]
(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	DMUAYZJ	Discovery agent	N.A.	Investigative	[63]
(S)-NORDULOXETINE	DMULFYA	Discovery agent	N.A.	Investigative	[62]
(S)-Norfluoxetine	DM8ZTPF	Discovery agent	N.A.	Investigative	[64]
1-(1,2-diphenylethyl)piperazine	DM0ARKB	Discovery agent	N.A.	Investigative	[65]
1-(1,4-diphenylbutan-2-yl)piperazine	DM8Z1QU	Discovery agent	N.A.	Investigative	[66]
1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	DMCSOAV	Discovery agent	N.A.	Investigative	[61]
1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	DMS9PZ7	Discovery agent	N.A.	Investigative	[61]
1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine	DM54ZKU	Discovery agent	N.A.	Investigative	[61]
1-(1-phenyl-2-o-tolylethyl)piperazine	DMZ6QX0	Discovery agent	N.A.	Investigative	[65]
1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine	DM0URSE	Discovery agent	N.A.	Investigative	[67]
1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine	DMJXKOF	Discovery agent	N.A.	Investigative	[68]
1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)	DMUJ2WB	Discovery agent	N.A.	Investigative	[61]
1-(2-(2-bromophenyl)-1-phenylethyl)piperazine	DMPRALC	Discovery agent	N.A.	Investigative	[65]
1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine	DM9CVX5	Discovery agent	N.A.	Investigative	[69]
1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine	DMUM4YQ	Discovery agent	N.A.	Investigative	[65]
1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine	DMBRS3D	Discovery agent	N.A.	Investigative	[65]
1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine	DMKWRCD	Discovery agent	N.A.	Investigative	[65]
1-(2-(2-fluorobenzyloxy)phenyl)piperazine	DM6XCPV	Discovery agent	N.A.	Investigative	[68]
1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine	DM2H38V	Discovery agent	N.A.	Investigative	[61]
1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine	DM4WEGM	Discovery agent	N.A.	Investigative	[65]
1-(2-(3-fluorophenoxy)phenyl)piperazine	DMXV2KQ	Discovery agent	N.A.	Investigative	[68]
1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine	DM8V5IH	Discovery agent	N.A.	Investigative	[65]
1-(2-(4-fluorophenoxy)phenyl)piperazine	DMU082P	Discovery agent	N.A.	Investigative	[68]
1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine	DMR4DJ1	Discovery agent	N.A.	Investigative	[58]
1-(2-(benzyloxy)phenyl)piperazine	DM0UZHL	Discovery agent	N.A.	Investigative	[68]
1-(2-(phenoxymethyl)phenyl)piperazine	DM7Z19T	Discovery agent	N.A.	Investigative	[68]
1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMBWCOZ	Discovery agent	N.A.	Investigative	[70]
1-(2-phenoxyphenyl)piperazine	DMWFCYN	Discovery agent	N.A.	Investigative	[68]
1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol	DMN4JU0	Discovery agent	N.A.	Investigative	[71]
1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol	DMWIEDN	Discovery agent	N.A.	Investigative	[71]
1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one	DM2SEXH	Discovery agent	N.A.	Investigative	[72]
1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one	DMFYJ5V	Discovery agent	N.A.	Investigative	[72]
1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one	DMPOVUY	Discovery agent	N.A.	Investigative	[72]
1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMPEZ1V	Discovery agent	N.A.	Investigative	[70]
1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMB9T6F	Discovery agent	N.A.	Investigative	[70]
1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one	DMW6YDK	Discovery agent	N.A.	Investigative	[72]
1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMPLEC0	Discovery agent	N.A.	Investigative	[70]
1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DM6ARQF	Discovery agent	N.A.	Investigative	[70]
1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMBV8PT	Discovery agent	N.A.	Investigative	[70]
1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DME435S	Discovery agent	N.A.	Investigative	[70]
1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one	DMU04ZQ	Discovery agent	N.A.	Investigative	[70]
1S,2R-milnacipran	DM7Y5AN	Discovery agent	N.A.	Investigative	[73]
2-((2-iodophenoxy)(phenyl)methyl)morpholine	DMS1AOK	Discovery agent	N.A.	Investigative	[74]
2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine	DMS21CR	Discovery agent	N.A.	Investigative	[74]
2-(2'-Aminoethyl)-5-benzyltetrahydrofuran	DMVTD1F	Discovery agent	N.A.	Investigative	[75]
2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine	DM56NK4	Discovery agent	N.A.	Investigative	[67]
2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine	DM1ULEX	Discovery agent	N.A.	Investigative	[69]
2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine	DM1SN37	Discovery agent	N.A.	Investigative	[69]
2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine	DMYVDJQ	Discovery agent	N.A.	Investigative	[69]
2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile	DMO9SP1	Discovery agent	N.A.	Investigative	[65]
2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran	DMU4MIC	Discovery agent	N.A.	Investigative	[75]
2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran	DMCUTY9	Discovery agent	N.A.	Investigative	[75]
2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran	DM157SO	Discovery agent	N.A.	Investigative	[75]
2-(Aminomethyl)-5-phenethyltetrahydrofuran	DMEZ7O2	Discovery agent	N.A.	Investigative	[75]
2-(N,N-Diethylamino)-3'-chloropropiophenone	DMVR248	Discovery agent	N.A.	Investigative	[76]
2-(N-Cyclopentylamino)-3'-bromopropiophenone	DML4GHA	Discovery agent	N.A.	Investigative	[72]
2-(N-Cyclopentylamino)-3'-chloropropiophenone	DMP68CE	Discovery agent	N.A.	Investigative	[76]
2-(N-Cyclopentylamino)-3'-fluoropropiophenone	DMH6FKX	Discovery agent	N.A.	Investigative	[72]
2-(N-Cyclopentylamino)-3'-methoxypropiophenone	DMVN1UI	Discovery agent	N.A.	Investigative	[72]
2-(N-Cyclopentylamino)-3'-methylpropiophenone	DMG87RK	Discovery agent	N.A.	Investigative	[72]
2-(N-Cyclopropylamino)-3-chloropropiophenone	DMNMES3	Discovery agent	N.A.	Investigative	[76]
2-(N-Pyrrolidinyl)-3'-bromopropiophenone	DM85ZCW	Discovery agent	N.A.	Investigative	[72]
2-(N-Pyrrolidinyl)-3'-fluoropropiophenone	DMYPOC5	Discovery agent	N.A.	Investigative	[72]
2-(N-Pyrrolidinyl)-3'-methoxypropiophenone	DM1W3L9	Discovery agent	N.A.	Investigative	[72]
2-(N-Pyrrolidinyl)-3'-methylpropiophenone	DMGKXOI	Discovery agent	N.A.	Investigative	[72]
2-(N-Pyrrolidinyl)-3'-nitropropiophenone	DM1I9LQ	Discovery agent	N.A.	Investigative	[72]
2-(N-tert-Butylamino)-3',4'-dichloropropiophenone	DMKIEVP	Discovery agent	N.A.	Investigative	[76]
2-(N-tert-Butylamino)-3'-chloroheptanophenone	DMY2PBO	Discovery agent	N.A.	Investigative	[76]
2-(N-tert-Butylamino)-3'-chlorohexanophenone	DMPO3CJ	Discovery agent	N.A.	Investigative	[76]
2-(N-tert-Butylamino)-3'-chlorooctanophenone	DMW47VA	Discovery agent	N.A.	Investigative	[76]
2-(N-tert-Butylamino)-3'-chloropentanophenone	DMTZ540	Discovery agent	N.A.	Investigative	[76]
2-(N-tert-Butylamino)propiophenone	DM9E5LT	Discovery agent	N.A.	Investigative	[76]
2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one	DMI457Y	Discovery agent	N.A.	Investigative	[72]
2-(tert-butylamino)-1-m-tolylpropan-1-one	DM6PV4W	Discovery agent	N.A.	Investigative	[72]
2-(tert-butylamino)-1-p-tolylpropan-1-one	DMYFQDT	Discovery agent	N.A.	Investigative	[72]
2-(tert-Butylamino)-3',4'-dichlorobutyrophenone	DMOJK8Y	Discovery agent	N.A.	Investigative	[76]
2-(tert-Butylamino)-3',4'-dichloropentanophenone	DMMUDQ7	Discovery agent	N.A.	Investigative	[76]
2-Amino-1-(4-methylthiophenyl)propane	DMJ2Z9G	Discovery agent	N.A.	Investigative	[77]
2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran	DMCJUWK	Discovery agent	N.A.	Investigative	[75]
2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran	DM3OTZY	Discovery agent	N.A.	Investigative	[75]
2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran	DMDG8FL	Discovery agent	N.A.	Investigative	[75]
2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran	DME4P7K	Discovery agent	N.A.	Investigative	[75]
2-Aminomethyl-5-(phenyl)tetrahydrofuran	DM413ZB	Discovery agent	N.A.	Investigative	[75]
2-phenoxy-3-(piperidin-4-yl)pyridine	DM6JNT5	Discovery agent	N.A.	Investigative	[69]
2pyrrolidin-1-yl-1-phenylpentan-1-one	DMBJXCF	Discovery agent	N.A.	Investigative	[70]
3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine	DMLV80B	Discovery agent	N.A.	Investigative	[78]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile	DM6YJOU	Discovery agent	N.A.	Investigative	[65]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	DM6QZTB	Discovery agent	N.A.	Investigative	[65]
3-(3'-furyl)-aniline	DM7FQVC	Discovery agent	N.A.	Investigative	[79]
3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine	DM2ETXB	Discovery agent	N.A.	Investigative	[69]
3-p-Tolyl-8-aza-bicyclo[3.2.1]octane	DM0872E	Discovery agent	N.A.	Investigative	[80]
3alpha-(bis-chloro-phenylmethoxy)tropane	DMBUZWQ	Discovery agent	N.A.	Investigative	[81]
4-((naphthalen-2-yloxy)methyl)piperidine	DMIQHYZ	Discovery agent	N.A.	Investigative	[58]
4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine	DM7Y1ZD	Discovery agent	N.A.	Investigative	[82]
4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine	DMJ9CNA	Discovery agent	N.A.	Investigative	[68]
4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine	DM9UA0N	Discovery agent	N.A.	Investigative	[68]
4-(2-(2-fluorobenzyloxy)phenyl)piperidine	DMCR3VM	Discovery agent	N.A.	Investigative	[68]
4-(2-(3-chlorophenoxy)phenyl)piperidine	DM0IT5E	Discovery agent	N.A.	Investigative	[68]
4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine	DMEPB9L	Discovery agent	N.A.	Investigative	[68]
4-(2-(3-fluorophenoxy)phenyl)piperidine	DMZMEOG	Discovery agent	N.A.	Investigative	[68]
4-(2-(4-fluorobenzyloxy)phenyl)piperidine	DM29QLG	Discovery agent	N.A.	Investigative	[68]
4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine	DMJNB8C	Discovery agent	N.A.	Investigative	[68]
4-(2-(4-fluorophenoxy)phenyl)piperidine	DMFQT9O	Discovery agent	N.A.	Investigative	[68]
4-(2-(benzyloxy)-3-fluorophenyl)piperidine	DMM2NHZ	Discovery agent	N.A.	Investigative	[68]
4-(2-(benzyloxy)-6-fluorophenyl)piperidine	DMF3S50	Discovery agent	N.A.	Investigative	[68]
4-(2-(benzyloxy)phenyl)piperidine	DMOC7PY	Discovery agent	N.A.	Investigative	[68]
4-(2-(phenoxymethyl)phenyl)piperidine	DM0OFRQ	Discovery agent	N.A.	Investigative	[68]
4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine	DMQUAP2	Discovery agent	N.A.	Investigative	[69]
4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine	DMUBHRF	Discovery agent	N.A.	Investigative	[68]
4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine	DMJ2GW0	Discovery agent	N.A.	Investigative	[68]
4-(2-fluoro-6-phenoxyphenyl)piperidine	DMXIGWC	Discovery agent	N.A.	Investigative	[68]
4-(2-phenoxyphenyl)piperidine	DMB5IFA	Discovery agent	N.A.	Investigative	[68]
4-(3'-furyl)-aniline	DMZ1TNM	Discovery agent	N.A.	Investigative	[79]
4-(3-fluoro-2-phenoxyphenyl)piperidine	DM1C3NZ	Discovery agent	N.A.	Investigative	[68]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[83]
6-(piperidin-4-ylmethoxy)-2-naphthonitrile	DMBQKGY	Discovery agent	N.A.	Investigative	[58]
7-(piperidin-4-ylmethoxy)-2-naphthonitrile	DM6I5K1	Discovery agent	N.A.	Investigative	[58]
8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane	DMOM4VS	Discovery agent	N.A.	Investigative	[80]
AMIFLAMINE	DMJ0BEG	Discovery agent	N.A.	Investigative	[67]
Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine	DM4D7V6	Discovery agent	N.A.	Investigative	[84]
Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine	DMTH4BG	Discovery agent	N.A.	Investigative	[85]
D-166A	DMQJD4P	Discovery agent	N.A.	Investigative	[86]
D-211A	DMIBOAK	Discovery agent	N.A.	Investigative	[86]
D-211B	DM54CKZ	Discovery agent	N.A.	Investigative	[86]
D-254C	DM6KFCO	Discovery agent	N.A.	Investigative	[86]
D-257A	DMN7E6Y	Discovery agent	N.A.	Investigative	[86]
D-257C	DM5GLJ2	Discovery agent	N.A.	Investigative	[86]
Difluorobenztropine	DM8ABD6	Discovery agent	N.A.	Investigative	[81]
Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine	DM293XH	Discovery agent	N.A.	Investigative	[87]
KF-A5	DMFBMYG	Discovery agent	N.A.	Investigative	[88]
MDL-28618	DMF76M8	Discovery agent	N.A.	Investigative	[57]
Methylenedioxyamphetamine	DMP204G	Discovery agent	N.A.	Investigative	[89]
Methylenedioxymethamphetamine	DMYVU47	Discovery agent	N.A.	Investigative	[90], [77]
MMDA	DMUWVGP	Discovery agent	N.A.	Investigative	[91]
N,N-dimethyl(2-phenoxyphenyl)methanamine	DMWK91T	Discovery agent	N.A.	Investigative	[92]
N-(2-oxazolemethyl)milnacipran	DMVGP02	Discovery agent	N.A.	Investigative	[93]
N-benzyl-N-isobutylpiperidin-4-amine	DM6QK7E	Discovery agent	N.A.	Investigative	[87]
N-desalkylquetiapine	DMBFC1U	Discovery agent	N.A.	Investigative	[94]
Nisoxetine	DMZBNH0	Discovery agent	N.A.	Investigative	[95]
norzotepine	DMS3N4X	Discovery agent	N.A.	Investigative	[96]
Para-chloroamphetamine	DMOH75D	Discovery agent	N.A.	Investigative	[77]
PF-18298	DMJMU09	Discovery agent	N.A.	Investigative	[61]
PF-3409409	DMEZA0T	Attention deficit hyperactivity disorder	6A05.Z	Investigative	[97]
PF-526014	DMD8QOZ	Discovery agent	N.A.	Investigative	[61]
POLYGALATENOSIDE B	DMUTV5P	Discovery agent	N.A.	Investigative	[98]
PTI-601	DMQUSXK	Pain	MG30-MG3Z	Investigative	[17]
Pyrovalerone	DMV48S2	Discovery agent	N.A.	Investigative	[70]
R-norduloxetine	DMGV4DS	Discovery agent	N.A.	Investigative	[62]
RTI-219	DM2QYXN	Discovery agent	N.A.	Investigative	[99]
S-34324	DMZLQ5W	Discovery agent	N.A.	Investigative	[100]
S33005	DM3Z6TI	Depression	6A70-6A7Z	Investigative	[101]
TQ-1017	DMEF32D	Pain	MG30-MG3Z	Investigative	[102]
Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine	DMEDC5I	Discovery agent	N.A.	Investigative	[85]
WAY-256805	DM48MC3	Pain	MG30-MG3Z	Investigative	[103]
WIN-35066-2	DMOX1S0	N. A.	N. A.	Investigative	[104]
[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine	DM4BYEQ	Discovery agent	N.A.	Investigative	[71]
[3H]nisoxetine	DMS3WNG	Discovery agent	N.A.	Investigative	[17]
[3H]WIN35428	DMI8RU0	Discovery agent	N.A.	Investigative	[105]
{2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine	DM3FBAZ	Discovery agent	N.A.	Investigative	[106]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Major depressive disorder	6A20	Pre-frontal cortex	7.05E-01	7.02E-03	0.07

The Drug Transporter (DTP) Role of This DTT

• DTT DTP Name: Sodium-dependent noradrenaline transporter (SLC6A2) DTP Info
• Gene Name: SLC6A2

2 Approved Drug(s) Transported by This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amphetamine	DMSZQAK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[107]
Norepinephrine	DMOUC09	Sepsis	1G40-1G41	Approved	[108]

References

• [1] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [2] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [3] Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
• [4] Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7.
• [5] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [6] A non-selective (amitriptyline), but not a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):285-90.
• [7] Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
• [8] Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
• [9] New drugs for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302.
• [10] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [11] Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
• [12] Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
• [13] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [14] Duloxetine for the treatment of generalized anxiety disorder: a review. Neuropsychiatr Dis Treat. 2009;5:23-31.
• [15] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [16] Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999 Mar 5;368(2-3):277-83.
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
• [18] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [19] Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
• [20] Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16.
• [21] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [22] Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63.
• [23] Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
• [24] Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
• [25] Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
• [26] Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55.
• [27] Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.
• [28] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [29] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [30] The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
• [31] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [32] Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
• [33] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [34] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [35] Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
• [36] Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6.
• [37] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [38] Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91.
• [39] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [40] Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34.
• [41] Clinical pipeline report, company report or official report of BioInvent.
• [42] Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
• [43] Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
• [44] Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6.
• [45] Company report (BioLineRx)
• [46] Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
• [47] Pfizer. Product Development Pipeline. March 31 2009.
• [48] Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9.
• [49] Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant
• [50] Clinical pipeline report, company report or official report of Neurosearch.
• [51] Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.Eur J Pharmacol.2014 Aug 15;737:47-56.
• [52] Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
• [53] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [54] Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31.
• [55] Clinical pipeline report, company report or official report of Neurosearch.
• [56] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598)
• [57] Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8.
• [58] Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
• [59] Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
• [60] Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2022-5.
• [61] Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
• [62] Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
• [63] Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
• [64] Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
• [65] N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
• [66] Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
• [67] Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12.
• [68] Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
• [69] Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
• [70] 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
• [71] Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
• [72] Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
• [73] Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72.
• [74] Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7.
• [75] 2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
• [76] Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
• [77] Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
• [78] Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70.
• [79] Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
• [80] 3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
• [81] Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
• [82] Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104.
• [83] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
• [84] Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9.
• [85] Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
• [86] Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
• [87] N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8.
• [88] Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40.
• [89] Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioampheta... Bioorg Med Chem. 2010 Jun 1;18(11):4009-31.
• [90] The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
• [91] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [92] 1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9.
• [93] Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9.
• [94] N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant ... Neuropsychopharmacology. 2008 Sep;33(10):2303-12.
• [95] Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4929-31.
• [96] Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81.
• [97] Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
• [98] Antidepressant principles of the roots of Polygala tenuifolia. J Nat Prod. 2006 Sep;69(9):1305-9.
• [99] Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95.
• [100] Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
• [101] Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
• [102] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [103] Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. J Med Chem. 2008 Jul 10;51(13):4038-49.
• [104] Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9.
• [105] 3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine trans... J Med Chem. 1996 Oct 11;39(21):4139-41.
• [106] Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(p... Bioorg Med Chem. 2009 Nov 15;17(22):7802-15.
• [107] Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
• [108] Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51.